Research analysts at Leerink Swann assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report issued on Friday, The Fly reports. The firm set a “market perform” rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on NKTR. Mizuho reiterated a “buy” rating and set a $81.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, January 23rd. ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th. HC Wainwright reaffirmed a “hold” rating and set a $47.00 price target on shares of Nektar Therapeutics in a research note on Tuesday, February 19th. Zacks Investment Research lowered Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 14th. Finally, BMO Capital Markets initiated coverage on Nektar Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $75.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company’s stock. Nektar Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $77.18.
Shares of NKTR opened at $36.32 on Friday. The stock has a market capitalization of $6.62 billion, a P/E ratio of 9.61 and a beta of 3.09. Nektar Therapeutics has a one year low of $29.22 and a one year high of $109.09. The company has a quick ratio of 17.39, a current ratio of 17.53 and a debt-to-equity ratio of 0.14.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.13. Nektar Therapeutics had a return on equity of 50.22% and a net margin of 57.09%. During the same period in the prior year, the company earned ($0.21) earnings per share. On average, research analysts anticipate that Nektar Therapeutics will post -3.01 EPS for the current year.
In other news, CEO Howard W. Robin sold 108,882 shares of the firm’s stock in a transaction on Thursday, February 21st. The stock was sold at an average price of $42.19, for a total transaction of $4,593,731.58. Following the completion of the sale, the chief executive officer now directly owns 350,924 shares of the company’s stock, valued at approximately $14,805,483.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Jillian B. Thomsen sold 1,808 shares of the firm’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $42.39, for a total value of $76,641.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 241,824 shares of company stock valued at $10,249,993. Corporate insiders own 4.31% of the company’s stock.
Institutional investors have recently modified their holdings of the company. CSat Investment Advisory L.P. boosted its position in shares of Nektar Therapeutics by 279.2% in the fourth quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 790 shares during the period. Laurel Wealth Advisors LLC purchased a new stake in shares of Nektar Therapeutics during the fourth quarter worth $39,000. Sandy Spring Bank purchased a new stake in shares of Nektar Therapeutics during the fourth quarter worth $59,000. Financial Architects Inc raised its holdings in shares of Nektar Therapeutics by 91.6% during the fourth quarter. Financial Architects Inc now owns 2,092 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of Nektar Therapeutics during the fourth quarter worth $101,000. 94.20% of the stock is owned by institutional investors and hedge funds.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Further Reading: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.